Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem Inc (NQ: VSTM )

3.865 -0.055 (-1.40%)
Streaming Delayed Price Updated: 2:44 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verastem Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
From Verastem Oncology
Via Business Wire
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
Although there’s safety in numbers, many times, you need to consider uncommon stocks to buy for growth for robust upside. 
Via InvestorPlace
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing. 
Via InvestorPlace
Where Verastem Stands With Analysts
Via Benzinga
Analyst Ratings for Verastem
Via Benzinga
Truist Securities Maintains Buy Rating for Verastem: Here's What You Need To Know
Via Benzinga
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
From Verastem Oncology
Via Business Wire
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
From Verastem Oncology
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
Verastem Oncology to Participate in Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
3 Penny Stocks That Can Triple Your Money in the Next 12 Months
Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing. 
Via InvestorPlace
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet... 
Via Talk Markets
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) shares gained 192.8% to $0.2427 in pre-market trading. Evelo Biosciences was granted U.S. patent #11672834 for "Prebiotic Compositions And Methods Of Use... 
Via Benzinga
Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 Results
U.S. stocks traded higher toward the end of trading, with Dow Jones gaining around 450 points on Thursday. The Dow traded up 1.32% to 34,429.39 while the NASDAQ rose 1.27% to 13,799.28. The S&P 500,... 
Via Benzinga
Verastem's Ovarian Cancer Drug Showing Promise, Analyst Upgrades Stock
Mizuho Securities has upgraded Verastem Inc (NASDAQ: VSTM) from Neutral to Buy with a price target of $36, up from $24, to  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.